Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Is a serotonin deficiency to blame for depression? Probably not, recent study finds. 

By Brian Buntz | July 21, 2022

depression image

[Image courtesy of Pexels]

A comprehensive review published in Molecular Psychiatry found scant evidence for the so-called serotonin hypothesis, suggesting that diminished serotonin pathways’ activity is associated with depression.

The authors conclude that the research provides “no consistent evidence of an association between serotonin and depression.” They also note they could not find support for “the hypothesis that depression is caused by lowered serotonin activity or concentrations.”

The Molecular Psychiatry article does, however, acknowledge that long-term use of antidepressants may lower serotonin concentration.

The broader idea that a chemical imbalance is to blame for depression has become a mainstream concept. The pioneering psychiatrist Joseph Schildkraut helped popularize the theory in the 1960s with a paper titled “The catecholamine hypothesis of affective disorders,” which would eventually become one of the most cited articles published by the American Journal of Psychiatry.

The related serotonin hypothesis of depression is now more than 50 years old.

Marketing for selective serotonin reuptake inhibitors (SSRIs) has helped cement its popularity. And research papers and textbooks backing the idea in recent decades have offered further support.

A Zoloft commercial noted that, “While the cause [of depression] is unknown, depression may be related to an imbalance of natural chemicals between nerve cells in the brain. Prescription Zoloft works to correct this imbalance.”

While several psychiatrists have called the serotonin hypothesis of depression an “urban legend,” the idea has remained influential.

A paper published earlier this year in SSM Mental Health found significant evidence for the theory in research papers and support in many textbooks. However, some of the latter acknowledged that the idea was provisional.

While professional opinions on antidepressants vary significantly, some papers have cast double on their efficacy in the past two decades.

One paper in BMJ concluded that the benefits of antidepressants for patients with major depressive disorder are likely “minimal.” It concludes that the drugs “should not be used for adults with major depressive disorder before valid evidence has shown that the potential beneficial effects outweigh the harmful effects.”


Filed Under: Psychiatric/psychotropic drugs
Tagged With: chemical imbalance, depression, serotonin hypothesis
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE